

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person* SPRINGER TIMOTHY A			2. Issuer Name and Ticker or Trading Symbol Cartesian Therapeutics, Inc. [RNAC]			5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)		
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 11/13/2023			6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person		
36 WOODMAN ROAD			4. If Amendment, Date of Original Filed (Month/Day/Year)			Rule 10b5-1(c) Transaction Indication		
(Street)						<input type="checkbox"/> Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.		
CHESTNUT HILL	MA	02467						
(City)	(State)	(Zip)						

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Series A Convertible Preferred Stock	11/15/2023		A		24,785.081	A	\$403.4685	24,785.081	I	See Footnote ⁽¹⁾
Series A Convertible Preferred Stock	11/15/2023		A		123,925.407	A	\$403.4685	123,925.407	D	
Common Stock								86,418	I	By wife
Common Stock								7,293,625	D	
Common Stock								29,868,490	I	See Footnote ⁽¹⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (Right to Buy)	\$17.47	11/13/2023		D			6,410	(2)	06/15/2027	Common Stock	6,410	(2)	0	D	
Stock Option (Right to Buy)	\$12.75	11/13/2023		D			10,000	(3)	06/14/2028	Common Stock	10,000	(3)	0	D	
Stock Option (Right to Buy)	\$2.1	11/13/2023		D			10,000	(4)	06/13/2029	Common Stock	10,000	(4)	0	D	
Stock Option (Right to Buy)	\$3	11/13/2023		D			20,000	(5)	06/18/2030	Common Stock	20,000	(5)	0	D	
Stock Option (Right to Buy)	\$4.01	11/13/2023		D			40,000	(6)	03/29/2031	Common Stock	40,000	(6)	0	D	
Stock Option (Right to Buy)	\$3.31	11/13/2023		D			40,000	(7)	01/02/2032	Common Stock	40,000	(7)	0	D	
Stock Option (Right to Buy)	\$1.13	11/13/2023		D			75,000	(8)	01/01/2033	Common Stock	75,000	\$0.93	0	D	

Explanation of Responses:

- Held by TAS Partners LLC. The reporting person is the managing member of TAS Partners LLC. The reporting person disclaims beneficial ownership of the securities held by TAS Partners LLC except to the extent of his pecuniary interest therein, if any.
- This option, which provided for vesting in full on June 14, 2018, was canceled in the merger (the "Merger") between Selecta Biosciences, Inc. and Cartesian Therapeutics, Inc.

3. This option, which provided for vesting in full on June 13, 2019, was canceled in the Merger.
4. This option, which provided for vesting in full on June 14, 2020, was canceled in the Merger.
5. This option, which provided for vesting in full on June 17, 2021, was canceled in the Merger.
6. This option, which provided for vesting in full on March 30, 2022, was canceled in the Merger.
7. This option, which provided for vesting in full on January 3, 2023, was canceled in the Merger.
8. This option, which provided for vesting in full on January 2, 2024, was canceled in the Merger in exchange for a cash payment of \$69,750, representing the difference between the exercise price of the option and \$2.06, the Cash-out Amount as applied in the Merger.

Remarks:

/s/ Matthew Bartholomae,
Attorney-in-Fact for Timothy 11/15/2023
A. Springer

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.